See https://www.ncl.ac.uk/press/articles/latest/2019/10/sjogrensyndromebreakthrough/
 | www.ncl.ac.uk A new study has shed light on a debilitating autoimmune condition by identifying a number of subtypes of the disease which could lead to personalised treatment for patients. For the first time, scientists at Newcastle University have found there are at least four versions of primary Sjögren's ... | |
Faculty Seminar
Speaker:
Kirsten Klein
Centre of Experimental Rheumatology, University Hospital Zurich
Venue:
MED.L2.6
Date:
Thursday 17th October 2019
Time:
11.30 – 12.30
Kirsten will present:
"Epigenetics of synovial fibroblasts"
Synovial fibroblasts are the most abundant stromal cells in joints that promote inflammation and drive joint destruction in rheumatoid arthritis. Synovial fibroblasts from different joint localizations exhibit profound differences in their expression profiles, which translate into a joint specific enrichment of arthritis relevant pathways, molecules and functional differences. Epigenetic factors act as intermediaries to link genetic and environmental risk factors to altered gene expression levels in a cell type-specific manner. Epigenetic mechanisms define the positional identity of synovial fibroblasts and underlie their role in persistent inflammation. Interfering with epigenetic modifications and their related epigenetic enzymes have therapeutic potential in rheumatoid arthritis.
Chair:
Professor John Isaacs
The PSORT (Psoriasis Stratification to Optimise Relevant Therapy) Stratified Medicine Consortium will host a one day Showcase event at the Royal College of Physicians, London to highlight its progress, achievements and plans for the future.
Formed by dermatologists, industry partners (including pharmaceutical companies), the British Association of Dermatologists and importantly, the Psoriasis Association, PSORT was established to determine whether it could predict which patients with psoriasis would respond best to a particular biologic drug. This, rather than the existing system of "trial and error" prescribing, would allow new treatment plans to be devised that would be personalised to the individual with psoriasis. If successful, such stratification might also achieve cost savings to the NHS and aid the pharmaceutical industry in the development of new drugs for psoriasis.
The Showcase will focus on how the key aspects of our programme have worked together for patient benefit. It will feature invited lectures by leading international speakers (academic, clinical, industry) interspersed amongst updates from scientists and clinicians from the PSORT team. These will be supplemented by a lunchtime poster exhibition. The day concludes with a networking wine reception.
The Showcase is free to attend and is open to the research community, industry, founders and patients alike.
Join us as we discuss how our findings might be of relevance to you.
To register, please use the BAD registration link https://www.eventsforce.net/bad/277/home
